Related Experiment Video
Updated: May 3, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
Multiparameter screening reveals a role for Na+ channels in cytokine-induced β-cell death
Yu Hsuan Carol Yang1, Yury Y Vilin, Michel Roberge
1Department of Cellular and Physiological Sciences (Y.H.C.Y., J.D.J.), Department of Anesthesiology, Pharmacology, and Therapeutics (Y.Y.V., H.T.K.), and Department of Biochemistry and Molecular Biology (M.R.), University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
Abstract:
Pancreatic β-cell death plays a role in both type 1 and type 2 diabetes, but clinical treatments that specifically target β-cell survival have not yet been developed. We have recently developed live-cell imaging-based, high-throughput screening methods capable of identifying factors that modulate pancreatic β-cell death, with the hope of finding drugs that can intervene in this process. In the present study, we used a high-content screen and the Prestwick Chemical Library of small molecules to identify drugs that block cell death resulting from exposure to a cocktail of cytotoxic cytokines (25 ng/mL TNF-α, 10 ng/mL IL-1β, and 10 ng/mL IFN-γ). Data analysis with self-organizing maps revealed that 19 drugs had profiles similar to that of the no cytokine condition, indicating protection. Carbamazepine, an antiepileptic Na(+) channel inhibitor, was particularly interesting because Na(+) channels are not generally considered targets for antiapoptotic therapy in diabetes and because the function of these channels in β-cells has not been well studied. We analyzed the expression and characteristics of Na(+) currents in mature β-cells from MIP-GFP mice. We confirmed the dose-dependent protective effects of carbamazepine and another use-dependent Na(+) channel blocker in cytokine-treated mouse islet cells. Carbamazepine down-regulated the proapoptotic and endoplasmic reticulum stress signaling induced by cytokines. Together, these studies point to Na(+) channels as a novel therapeutic target in diabetes.
Insights
Pancreatic beta-cell death contributes to diabetes. Researchers identified carbamazepine, a sodium channel blocker, as a drug that protects beta-cells from death, suggesting a new therapeutic target for diabetes.
Area of Science:
- Endocrinology
- Cell Biology
- Pharmacology
Background:
- Pancreatic beta-cell death is implicated in type 1 and type 2 diabetes.
- Current treatments do not specifically target beta-cell survival.
- Novel therapeutic strategies are needed to prevent beta-cell loss.
Purpose of the Study:
- To identify small molecules that protect pancreatic beta-cells from cytotoxic cytokine-induced death.
- To investigate the role of sodium channels in beta-cell survival.
- To explore carbamazepine as a potential therapeutic agent for diabetes.
Main Methods:
- High-content screening of the Prestwick Chemical Library against cytokine-treated beta-cells.
- Analysis of sodium channel expression and function in mouse beta-cells.
- Assessment of carbamazepine's effects on cell death and signaling pathways.
Main Results:
- Nineteen drugs demonstrated protective effects against cytokine-induced beta-cell death.
- Carbamazepine, a sodium channel inhibitor, showed significant dose-dependent protection.
- Carbamazepine reduced pro-apoptotic and endoplasmic reticulum stress signaling.
Conclusions:
- Sodium channels represent a novel therapeutic target for preserving pancreatic beta-cell function in diabetes.
- Carbamazepine demonstrates potential as a protective agent for beta-cells.
- Further research into sodium channel modulation could lead to new diabetes treatments.

